| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Contract Research | 12.6 | 13.4 | 13.3 | 12.6 | 13.1 | | | |
| Dermatology Therapeutics | 25.4 | 0.9 | 0.7 | | 1.5 | | | |
| Total revenues [+] | 29.8 | 6.8 | 6.5 | 4.2 | 6.2 | 1.7 | 0.0 | 0.0 |
| Licensing | 7.9 | | | | | | | |
| Revenue growth [+] | 340.1% | 4.3% | 53.3% | -31.3% | 265.5% | | | |
| Contract Research | -6.3% | 1.0% | 5.7% | -4.1% | | | | |
| Dermatology Therapeutics | 2620.6% | 33.9% | | | | | | |
| Cost of goods sold | 4.0 | 4.7 | 5.1 | 4.1 | 4.3 | 1.2 | 0.0 | 0.0 |
| Gross profit | 25.7 | 2.0 | 1.3 | 0.2 | 1.8 | 0.5 | 0.0 | 0.0 |
| Gross margin | 86.5% | 30.3% | 20.8% | 4.1% | 29.6% | 28.3% | | |
| Selling, general and administrative [+] | 25.1 | 23.6 | 20.5 | 27.8 | 25.8 | 19.0 | 15.1 | 5.3 |
| Sales and marketing | | | | | | 0.1 | 3.3 | |
| General and administrative | 25.1 | 23.6 | 20.5 | 27.8 | 25.8 | 18.9 | 11.8 | 5.3 |
| Research and development | 77.8 | 43.8 | 29.3 | 64.2 | 60.8 | 35.8 | 33.5 | 15.3 |
| Other operating expenses | 7.9 | | | 0.7 | | | | |
| EBITDA [+] | -84.4 | -64.5 | -47.2 | -86.1 | -82.9 | -54.0 | -48.4 | -20.6 |
| EBITDA growth | 30.9% | 36.6% | -45.2% | 3.9% | 53.6% | 11.4% | 135.4% | 141.5% |
| EBITDA margin | -283.5% | -953.4% | -728.1% | -2038.0% | -1347.8% | -3206.1% | | |
| Depreciation | 0.7 | 0.8 | 1.2 | 6.3 | 1.8 | 0.4 | 0.1 | 0.1 |
| EBITA | -85.1 | -65.3 | -48.4 | -92.5 | -84.7 | -54.3 | -48.6 | -20.7 |
| EBITA margin | -286.0% | -966.0% | -747.4% | -2187.8% | -1377.1% | -3228.2% | | |
| Amortization of intangibles | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | | |
| EBIT [+] | -85.2 | -65.4 | -48.5 | -92.6 | -84.8 | -54.4 | -48.6 | -20.7 |
| EBIT growth | 30.2% | 34.8% | -47.6% | 9.2% | 56.0% | 11.9% | 135.0% | 142.2% |
| EBIT margin | -286.2% | -967.1% | -748.5% | -2189.6% | -1378.3% | -3230.0% | | |
| Non-recurring items [+] | 4.7 | 24.3 | 2.4 | 18.5 | | | | |
| Asset impairment | | | | 18.5 | | | | |
| Loss on contingent liability | 4.7 | 24.3 | 2.4 | | | | | |
| Other income (expense), net [+] | 2.9 | -1.1 | -0.4 | -2.5 | 2.7 | -16.0 | 0.5 | 0.1 |
| Change in value of contingent liability | | | | 0.7 | | | | |
| Other | 2.9 | -1.1 | -0.4 | -2.5 | 2.7 | 2.1 | 0.5 | 0.1 |
| Pre-tax income | -86.9 | -90.9 | -51.3 | -113.5 | -82.1 | -70.4 | -48.1 | -20.6 |
| Income taxes | 0.0 | 0.0 | -0.2 | 47.8 | 50.6 | -1.8 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.4% | | | 2.6% | 0.0% | 0.0% |
| Earnings from continuing ops | -86.9 | -90.9 | -51.2 | -113.5 | -82.1 | -52.3 | -48.1 | -23.1 |
| Earnings from discontinued ops | | | | | -50.6 | -18.1 | | |
| Net income | -86.9 | -90.9 | -51.0 | -161.4 | -132.7 | -68.5 | -48.1 | -23.1 |
| Net margin | -292.1% | -1344.0% | -787.0% | -3817.2% | -2158.0% | -4071.5% | | |
| |
| Basic EPS [+] | ($1.33) | ($1.60) | ($1.20) | ($2.75) | ($2.49) | ($1.86) | ($2.25) | ($3.79) |
| Growth | -16.8% | 33.2% | -56.2% | 10.1% | 34.1% | -17.1% | -40.7% | -38.4% |
| Diluted EPS [+] | ($1.33) | ($1.60) | ($1.20) | ($2.75) | ($2.49) | ($1.86) | ($2.25) | ($3.79) |
| Growth | -16.8% | 33.2% | -56.2% | 10.1% | 34.1% | -17.1% | -40.7% | -38.4% |
| |
| Shares outstanding (basic) [+] | 65.2 | 56.7 | 42.5 | 41.3 | 32.9 | 28.1 | 21.4 | 6.1 |
| Growth | 15.0% | 33.4% | 2.9% | 25.6% | 17.1% | 31.2% | 250.7% | 255.0% |
| Shares outstanding (diluted) [+] | 65.2 | 56.7 | 42.5 | 41.3 | 32.9 | 28.1 | 21.4 | 6.1 |
| Growth | 15.0% | 33.4% | 2.9% | 25.6% | 17.1% | 31.2% | 250.7% | 255.0% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |